



## UROLOGICAL SOCIETY OF AUSTRALIA AND NEW ZEALAND

**Media Release - for Immediate Release**

### **Urological Society welcomes listing of prostate drug for Australian men**

The Urological Society of Australia and New Zealand welcomes Health Minister Roxon's announcement that Duodart® (Dutasteride with tamsulosin hydrochloride), a drug for the treatment of benign prostate enlargement, will be subsidised under the Pharmaceutical Benefits Scheme.

"This is good news for the many Australian men who suffer this uncomfortable condition, and we are pleased they will have access to this treatment at a more affordable price," says Dr Stephen Ruthven.

"While benign prostate enlargement is not a life-threatening condition, it does have a serious impact on sufferers' quality of life, and can be a significant cause of anxiety, embarrassment and discomfort" says Dr Ruthven.

Approximately 50% of all Australian men over the age of 50 will experience benign prostate enlargement at some stage.

The symptoms include difficulty urinating, or an urgent and frequent need to urinate, particularly throughout the night, and in some cases incontinence.

If left untreated it may lead to further complications such as bladder or urinary tract infections.

***For further information or to interview a representative of the Urological Society of Australia and New Zealand, please contact Edwina Gatenby, Maxicom Public Relations, ph. 02 9965 9302 or 0402 130 254.***

(The Urological Society is the peak professional body for urologists. Urologists are surgeons who treat men, women and children with problems involving the kidney, bladder, prostate and male reproductive organs. These conditions include cancer, stones, infection, incontinence, sexual dysfunction and pelvic floor problems.)